Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Hepatol. Jul 27, 2012; 4(7): 218-223
Published online Jul 27, 2012. doi: 10.4254/wjh.v4.i7.218
Table 1 Study population baseline characteristics (491 patients)
Patients baseline characteristics
Female gender, n (%)360/491 (73.3)
Median age, yr (IQR)35 (30-41)
BMI (kg/m2), n (%) < 18.5 18.5-25 > 25115 (23.4) 281 (57.2) 95 (19.4)
WHO clinical stage, n (%) 1 or 2 3 or 4294/491 (60) 197/491 (40)
HIV serology, n (%) HIV-1 HIV-1 and HIV-2476 (97) 15 (3)
Median CD4+ T-cell count (/mm3) (IQR)341 (221-470)
CD4+ T-cell < 200/mm3, n (%)112/491 (22.8)
Median plasma HIV RNA (Log10 copies/mL) (IQR)4.87 (4.15-5.45)
Plasma HIV-1 RNA > 5 log10 copies/mL, n (%)221/491 (45)
Serum transaminase level, n (%) AST > UNV81/491 (16.5)
ALT > UNV41/491 (8.4)
Table 2 Hepatitis B virus DNA quantitative values by hepatitis B virus infection type
Type of viral BinfectionViral infection B DNA (UI/mL)
MedianInterquartilerangeRange
HBeAg positive hepatitis2.1 × 1071.1 × 107-1.1 × 10827200-1.1 × 108
HBeAg negative hepatitis139 0008760-1.1 × 1083030-1.1 × 108
Viral B inactive chronic carriers33162-6418-1540
Occult B infection4616-1497-258
Table 3 Relationship between HBs antigen positivity and baseline characteristics
Baseline characteristicsUnivariate analysisMultivariate analysis
HBsAg (+)1n = 66 (%)HBsAg (-)1n = 425 (%)P valueOR (95% CI)n = 491P value
Age > 35 yr257.6480.15--
Gender, male43.9240.0012.2 (1.3-3.8)0.005
BMI < 18.5 kg/m234.921.70.06--
WHO stage 4313.63.80.0033.2 (1.3-7.9)0.01
AST > UNV30.314.40.0011.9 (1.02-3.6)0.04
ALT > UNV16.77.10.009--
CD4+ T-cell < 200/mm334.920.90.01--
HIV RNA ≥ 5 Log59.142.80.021.5 (0.9-2.7)0.12